JPRN-UMIN000016383CompletedPhase 2
Phase II study of docetaxel monotherapy plus primary prophylaxis with pegfilgrastim for pre-treated locally advanced or metastatic non-small cell lung cancer. - OPH-RM-LC-1501
Dept. Respiratory Medicine, Osaka Police Hopital0 sites31 target enrollmentStarted: February 2, 2015Last updated:
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 31
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •(1) A history of docetaxel treatment (2)Current or previous history of pulmonary fibrosis, interstitial pneumonitis or drug-induced pneumonia, revealed by chest X-ray film (3)Concurrent thoracic radiotherapy (4) A history of severe hypersensitivity against docetaxel or pegfilgrastim (5)Another active advanced malignancy that requires any concurrent treatment with treatment for lung cancer (6)Pleural effusion, ascites or peri-cardiac effusion requiring dranage. (7)Problematic complications (8) Pregnant or lactation women, or women with known or suspected pregnancy and men who want let to pregnancy (9) Decision of ineligibility by a physician
Investigators
Similar Trials
Completed
Not Applicable
Phase I/II study of the combination of docetaxel, CDDP and S-1 in patients with unresectable advanced gastric cancerunresectable advanced gastric cancerJPRN-C000000080Fourth Department of Internal Medicine, Sapporo Medical University40
Completed
Phase 1
Phase I/II trial of weekly docetaxel and concomitant radiotherapy for unresectable esophageal squamous cell carcinoma after induction chemothrapynresectable esophageal squamous cell carcinoma after induction chemotherapyJPRN-UMIN000004856Gastroenterologic surgery, Kanazawa university44
Active, not recruiting
Phase 1
A phase I/II study of docetaxel plus prednisolone plus diethylstilbestrol plus aspirin in androgen-independent prostate cancerHormone refractory prostate cancerEUCTR2005-002027-13-GBRoyal Marsden NHS FOundation Trust37
Active, not recruiting
Not Applicable
A randomized phase II study of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. - DOCOX GASTRIC (Docetaxel-Oxaliplatin in Gastric Cancer)Metastatic or local recurrent gastric cancer previously untreated with chemotherapy for advance disease.MedDRA version: 8.1Classification code 10017758EUCTR2005-005464-92-HUSanofi-aventis groupe270
Active, not recruiting
Not Applicable
A randomized phase II study of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. - GATE (GAstric cancer study with Taxotere-Eloxatin-based regimens)Metastatic or local recurrent gastric cancer previously untreated with chemotherapy for advance disease.MedDRA version: 8.1Classification code 10017758EUCTR2005-005464-92-BESanofi-aventis groupe270